A Phase II Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Multiple Formulations of an RSV F Particle Vaccine With Aluminum, in Healthy Women of Child-Bearing Age

Trial Profile

A Phase II Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Multiple Formulations of an RSV F Particle Vaccine With Aluminum, in Healthy Women of Child-Bearing Age

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs RSV F protein vaccine-Novavax (Primary) ; Aluminium phosphate
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novavax
  • Most Recent Events

    • 07 Jun 2017 Results published in the journal Vaccine, according to a Novavax media release.
    • 07 Jun 2017 Results published in a Novavax media release.
    • 29 Apr 2014 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top